Clinical Trial Update: Sintilimab to Prevent High-risk Oral Premalignant Lesions Cancerization [Phase 2]

View source ↗

Summary

A Phase 2 trial update on sintilimab aimed at preventing cancerization in high-risk oral premalignant lesions.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mouth Neoplasm
• Oral Cavity Cancer
• Oral Premalignant Lesions

Drugs mentioned

• Sintilimab (sintilimab)

Snippet

Sponsor: Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | Conditions: Oral Cavity Cancer, Mouth Neoplasm | Phase 2 | Status: UNKNOWN